251 related articles for article (PubMed ID: 32166411)
1. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
[TBL] [Abstract][Full Text] [Related]
2. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
[TBL] [Abstract][Full Text] [Related]
3. Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC).
Patil SM; Sawant SS; Kunda NK
Int J Pharm; 2021 Sep; 607():121046. PubMed ID: 34450225
[TBL] [Abstract][Full Text] [Related]
4. Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy.
Elbatanony RS; Parvathaneni V; Kulkarni NS; Shukla SK; Chauhan G; Kunda NK; Gupta V
Drug Deliv Transl Res; 2021 Jun; 11(3):927-943. PubMed ID: 32557351
[TBL] [Abstract][Full Text] [Related]
5. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
6. Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics.
Vaidya B; Kulkarni NS; Shukla SK; Parvathaneni V; Chauhan G; Damon JK; Sarode A; Garcia JV; Kunda N; Mitragotri S; Gupta V
Int J Pharm; 2020 Mar; 577():118995. PubMed ID: 31935471
[TBL] [Abstract][Full Text] [Related]
7. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of
Zhong T; Liu X; Li H; Zhang J
Drug Deliv; 2021 Dec; 28(1):2108-2118. PubMed ID: 34607478
[TBL] [Abstract][Full Text] [Related]
9. Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer.
Wang X; Parvathaneni V; Shukla SK; Kulkarni NS; Muth A; Kunda NK; Gupta V
Int J Biol Macromol; 2020 Dec; 164():638-650. PubMed ID: 32693132
[TBL] [Abstract][Full Text] [Related]
10. Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.
Youngren-Ortiz SR; Hill DB; Hoffmann PR; Morris KR; Barrett EG; Forest MG; Chougule MB
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):299-321. PubMed ID: 28277892
[TBL] [Abstract][Full Text] [Related]
11. Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles.
Li N; Chen Y; Sun H; Huang T; Chen T; Jiang Y; Yang Q; Yan X; Wu M
Pharm Dev Technol; 2020 Jun; 25(5):556-565. PubMed ID: 31958240
[No Abstract] [Full Text] [Related]
12. Cationically modified inhalable nintedanib niosomes: enhancing therapeutic activity against non-small-cell lung cancer.
K Shukla S; Nguyen V; Goyal M; Gupta V
Nanomedicine (Lond); 2022 Jun; 17(13):935-958. PubMed ID: 36004583
[No Abstract] [Full Text] [Related]
13. Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles.
Nafee N; Gaber DM; Elzoghby AO; Helmy MW; Abdallah OY
Pharm Res; 2020 Apr; 37(4):82. PubMed ID: 32291520
[TBL] [Abstract][Full Text] [Related]
14. Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
Yadav KS; Raut HC; Nijhawan HP
Pharm Dev Technol; 2023 Oct; 28(8):755-767. PubMed ID: 37665569
[TBL] [Abstract][Full Text] [Related]
15. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model.
Roa WH; Azarmi S; Al-Hallak MH; Finlay WH; Magliocco AM; Löbenberg R
J Control Release; 2011 Feb; 150(1):49-55. PubMed ID: 21059378
[TBL] [Abstract][Full Text] [Related]
16. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
18. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy.
Elgohary MM; Helmy MW; Abdelfattah EA; Ragab DM; Mortada SM; Fang JY; Elzoghby AO
J Control Release; 2018 Sep; 285():230-243. PubMed ID: 30009892
[TBL] [Abstract][Full Text] [Related]
19. Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer.
Moin A; Wani SUD; Osmani RA; Abu Lila AS; Khafagy ES; Arab HH; Gangadharappa HV; Allam AN
Drug Deliv; 2021 Dec; 28(1):1626-1636. PubMed ID: 34328806
[TBL] [Abstract][Full Text] [Related]
20. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma.
Kabary DM; Helmy MW; Abdelfattah EA; Fang JY; Elkhodairy KA; Elzoghby AO
Eur J Pharm Biopharm; 2018 Sep; 130():152-164. PubMed ID: 29964122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
